rosiglitazone has been researched along with obeticholic acid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Antonelli, E; Fiorucci, S; Mencarelli, A; Morelli, A; Pellicciari, R; Pruzanski, M; Renga, B; Riccardi, L; Rizzo, G | 1 |
| Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
2 review(s) available for rosiglitazone and obeticholic acid
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
2 other study(ies) available for rosiglitazone and obeticholic acid
| Article | Year |
|---|---|
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
Topics: Animals; Cells, Cultured; Chenodeoxycholic Acid; DNA-Binding Proteins; Gene Expression Regulation; Humans; Liver; Liver Cirrhosis, Experimental; PPAR gamma; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2005 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |